MX2022006072A - Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel. - Google Patents

Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.

Info

Publication number
MX2022006072A
MX2022006072A MX2022006072A MX2022006072A MX2022006072A MX 2022006072 A MX2022006072 A MX 2022006072A MX 2022006072 A MX2022006072 A MX 2022006072A MX 2022006072 A MX2022006072 A MX 2022006072A MX 2022006072 A MX2022006072 A MX 2022006072A
Authority
MX
Mexico
Prior art keywords
skin
methods
subject
polypeptide
compositions
Prior art date
Application number
MX2022006072A
Other languages
English (en)
Inventor
Suma Krishnan
Pooja Agarwal
Original Assignee
Krystal Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57822104&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022006072(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krystal Biotech Inc filed Critical Krystal Biotech Inc
Publication of MX2022006072A publication Critical patent/MX2022006072A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1748—Keratin; Cytokeratin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
    • C12Y114/11004—Procollagen-lysine 5-dioxygenase (1.14.11.4), i.e. lysine-hydroxylase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

La presente revelación tiene relación, en parte, con composiciones farmacéuticas que comprenden uno o más polinucleótidos adecuados para potenciar, aumentar, y/o suplementar los niveles de polipéptidos de cadena de Colágeno alfa-1 (VII) y/o polipéptido de lisil hidroxilasa 3 y/o polipéptido del citoesqueleto 17 de queratina tipo I en un sujeto. La presente revelación también tiene relación, en parte, a composiciones farmacéuticas y a métodos de uso para proporcionar alivio profiláctico, paliativo o terapéutico de una herida, trastorno o enfermedad de la piel en un sujeto, incluyendo un sujeto que tiene, o está en riesgo de desarrollar, uno o más síntomas de epidermólisis ampollosa.
MX2022006072A 2016-04-08 2018-10-04 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel. MX2022006072A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662320316P 2016-04-08 2016-04-08

Publications (1)

Publication Number Publication Date
MX2022006072A true MX2022006072A (es) 2022-06-14

Family

ID=57822104

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018012135A MX2018012135A (es) 2016-04-08 2016-12-28 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
MX2022006072A MX2022006072A (es) 2016-04-08 2018-10-04 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018012135A MX2018012135A (es) 2016-04-08 2016-12-28 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.

Country Status (21)

Country Link
US (7) US9877990B2 (es)
EP (2) EP3377637B1 (es)
JP (3) JP6970086B2 (es)
KR (1) KR20180128016A (es)
CN (1) CN109072255A (es)
AU (3) AU2016401692B2 (es)
CA (1) CA3017487A1 (es)
CL (3) CL2018002814A1 (es)
CY (1) CY1123024T1 (es)
DK (1) DK3377637T3 (es)
ES (1) ES2796488T3 (es)
HR (1) HRP20200853T1 (es)
HU (1) HUE049237T2 (es)
LT (1) LT3377637T (es)
MX (2) MX2018012135A (es)
PL (1) PL3377637T3 (es)
PT (1) PT3377637T (es)
RS (1) RS60410B1 (es)
SG (1) SG11201808314QA (es)
SI (1) SI3377637T1 (es)
WO (1) WO2017176336A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201705069YA (en) 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
PL3377637T3 (pl) * 2016-04-08 2020-09-07 Krystal Biotech, Inc. Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry
US10864153B2 (en) * 2016-11-14 2020-12-15 The Regents Of The University Of Michigan Compositions and methods for blocking ultraviolet radiation
EP3568474A1 (en) 2017-01-10 2019-11-20 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
EP3706762A4 (en) 2017-12-07 2021-09-01 Emory University N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES IN RELATION TO IT
WO2019200163A1 (en) 2018-04-12 2019-10-17 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
KR20210005141A (ko) * 2018-04-27 2021-01-13 크리스탈 바이오테크, 인크. 미적 적용을 위한 미용 단백질(들)을 인코딩하는 재조합 핵산
WO2020068862A1 (en) 2018-09-24 2020-04-02 Krystal Biotech, Inc. Compositions and methods for the treatment of netherton syndrome
EP3856914A1 (en) * 2018-09-26 2021-08-04 Krystal Biotech, Inc. Compositions and methods for the treatment of skin diseases
JPWO2020149395A1 (ja) * 2019-01-18 2021-11-25 国立大学法人大阪大学 栄養障害型表皮水疱症治療薬
AU2020219343A1 (en) 2019-02-08 2021-08-19 Krystal Biotech, Inc. Compositions and methods for delivering CFTR polypeptides
TWI818166B (zh) * 2019-03-27 2023-10-11 美商菲尼克斯組織修復公司 用於生產膠原蛋白7組合物之系統及方法
AU2020341451A1 (en) 2019-09-03 2022-03-24 Krystal Biotech, Inc. Compositions and methods for the treatment of congenital ichthyoses
CN112724225B (zh) * 2019-10-28 2023-09-26 中国医学科学院药物研究所 一种角蛋白bd-6、制法和其药物组合物与用途
EP4077688A1 (en) 2019-12-20 2022-10-26 Krystal Biotech, Inc. Compositions and methods for gene delivery to the airways and/or lungs
BR112023020209A2 (pt) 2021-04-02 2023-12-19 Krystal Biotech Inc Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, uso do vírus do herpes ou da composição farmacêutica, método para expressar, realçar, aumentar, ampliar e/ou suplementar os níveis de um polipeptídeo imunomodulatório, método para prover alívio profilático, paliativo ou terapêutico, e, método para tratar câncer
WO2023064806A1 (en) 2021-10-12 2023-04-20 Phoenix Tissue Repair, Inc. Collagen 7 protein replacement therapy
CN117143223B (zh) * 2022-08-23 2024-03-08 山西锦波生物医药股份有限公司 一种生物合成人体结构性材料的制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5658724A (en) 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
ATE388720T1 (de) * 1997-04-10 2008-03-15 Univ Southern California Sich an extrazelluläre matrixbestandteile anbindende modifizierte proteine
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9715085D0 (en) * 1997-07-18 1997-09-24 Jahoda Amanda J Gene therapy vehicle
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
GB9801930D0 (en) * 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
EP1083951A4 (en) * 1998-06-12 2004-07-07 Aradigm Corp METHOD FOR DISCHARGING POLYNUCLEOTIDS IN THE FORM OF AN AEROSOL IN THE RESPIRATION WAY
CA2356937A1 (en) 1998-12-31 2000-07-13 Richard J. Whitley Recombinant herpes simplex virus useful for treating neoplastic disease
GB9930418D0 (en) * 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
CA2430341A1 (en) * 2000-11-28 2002-06-06 The University Of Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2006050211A2 (en) * 2004-10-28 2006-05-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
WO2006079014A2 (en) * 2005-01-21 2006-07-27 Introgen Therapeutics, Inc. Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
AU2006252406B2 (en) * 2005-06-01 2012-05-17 California Institute Of Technology Method of targeted gene delivery using viral vectors
US8703703B2 (en) * 2006-12-20 2014-04-22 University Of Central Flordia Research Foundation, Inc. MCPIP as wound therapy
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
US20080289058A1 (en) * 2007-05-14 2008-11-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
US20100081707A1 (en) * 2008-02-21 2010-04-01 Ali Robin R Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
CN102212559B (zh) 2011-04-14 2014-04-09 郑州威瑞生物技术有限公司 一种重组的hsv扩增子载体及其用途
US9340783B2 (en) * 2011-10-11 2016-05-17 Inserm (Institut National De La Sante Et De La Recherche Medicale Exon skipping therapy for dystrophic epidermolysis bullosa
GB201202561D0 (en) 2012-02-15 2012-03-28 Univ Dundee Treatment of skin disorders
CA2873881A1 (en) * 2012-05-18 2013-11-21 Stephen Bruce Fleming Combination treatments and compositions for wound healing
JP6480874B2 (ja) * 2013-03-01 2019-03-13 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタＲｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｎｎｅｓｏｔａ Ｔａｌｅｎに基づく遺伝子修正
PL2968586T3 (pl) * 2013-03-14 2019-01-31 Translate Bio, Inc. Kompozycje mrna cftr i związne z nimi sposoby i zastosowania
US10174341B2 (en) 2013-07-17 2019-01-08 University of Pittsburgh—of the Commonwealth System of Higher Education Non-toxic HSV vectors for efficient gene delivery applications and complementing cells for their production
JP6588024B2 (ja) * 2013-10-28 2019-10-09 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 腫瘍溶解性ｈｓｖベクター
KR20220100078A (ko) 2014-01-31 2022-07-14 팩터 바이오사이언스 인크. 핵산 제조 및 송달을 위한 방법 및 산물
GB2526339A (en) * 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
US20160082129A1 (en) * 2014-09-24 2016-03-24 Aerpio Therapeutics, Inc. VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
CN113559246A (zh) * 2014-10-31 2021-10-29 京都府公立大学法人 使用层粘连蛋白的新的角膜的治疗
US20180148711A1 (en) * 2015-05-28 2018-05-31 Coda Biotherapeutics, Inc. Genome editing vectors
WO2017106202A2 (en) * 2015-12-14 2017-06-22 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
ES2924521T3 (es) * 2016-03-25 2022-10-07 Periphagen Inc Vectores del VHS para la administración de NT3, y tratamiento de la CIPN
DK3432912T3 (da) * 2016-03-25 2023-03-13 Periphagen Inc Hsv-vektorer med høj transduktion
PL3377637T3 (pl) 2016-04-08 2020-09-07 Krystal Biotech, Inc. Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry
WO2019200163A1 (en) 2018-04-12 2019-10-17 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
KR20210005141A (ko) 2018-04-27 2021-01-13 크리스탈 바이오테크, 인크. 미적 적용을 위한 미용 단백질(들)을 인코딩하는 재조합 핵산
AU2019292580A1 (en) 2018-06-29 2021-02-04 Krystal Biotech, Inc. Compositions and methods for antibody delivery

Also Published As

Publication number Publication date
KR20180128016A (ko) 2018-11-30
US20200101123A1 (en) 2020-04-02
US11865148B2 (en) 2024-01-09
CL2023000743A1 (es) 2023-09-29
SI3377637T1 (sl) 2020-08-31
JP2023118838A (ja) 2023-08-25
CY1123024T1 (el) 2021-10-29
AU2022204729A1 (en) 2022-07-21
RS60410B1 (sr) 2020-07-31
EP3377637A1 (en) 2018-09-26
AU2016401692A1 (en) 2018-09-27
LT3377637T (lt) 2020-07-10
US20170290866A1 (en) 2017-10-12
EP3377637B1 (en) 2020-03-18
HRP20200853T1 (hr) 2020-08-21
WO2017176336A1 (en) 2017-10-12
NZ746213A (en) 2021-08-27
US10441614B2 (en) 2019-10-15
US20230149486A1 (en) 2023-05-18
US20220273737A1 (en) 2022-09-01
ES2796488T3 (es) 2020-11-27
JP2019513689A (ja) 2019-05-30
PT3377637T (pt) 2020-06-17
US20190160122A1 (en) 2019-05-30
AU2016401692B2 (en) 2019-10-03
DK3377637T3 (da) 2020-05-18
SG11201808314QA (en) 2018-10-30
US9877990B2 (en) 2018-01-30
JP6970086B2 (ja) 2021-11-24
AU2019280069B2 (en) 2022-04-07
AU2019280069A1 (en) 2020-01-16
JP7480105B2 (ja) 2024-05-09
US10155016B2 (en) 2018-12-18
MX2018012135A (es) 2019-03-28
EP3712273A1 (en) 2020-09-23
HUE049237T2 (hu) 2020-09-28
US20230414686A1 (en) 2023-12-28
CL2021000881A1 (es) 2021-09-10
CL2018002814A1 (es) 2019-02-15
PL3377637T3 (pl) 2020-09-07
US11185564B2 (en) 2021-11-30
CA3017487A1 (en) 2017-10-12
JP2022023174A (ja) 2022-02-07
US20180169160A1 (en) 2018-06-21
CN109072255A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
MX2022006072A (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
WO2020047462A3 (en) Methods of treating aging-related disorders
AU2017260706A1 (en) Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
EA202091144A1 (ru) Ганаксолон для использования в лечении наследственных эпилептических заболеваний
MX2019004549A (es) Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos.
MX2020005547A (es) Moduladores de la actividad del complemento.
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2019002211A (es) Composiciones de nicotinamida ribosido y pterostilbeno y metodos para el tratamiento de trastornos neurodegenerativos.
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
WO2019246262A3 (en) Methods of treating or inhibiting onset of huntington's disease
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
WO2011146674A3 (en) Treatment of bcl2-like 11 (bcl2l11) related diseases by inhibition of natural antisense transcript to bcl2l11
WO2011146675A3 (en) Treatment of lim homeobox 2 (lhx2) related diseases by inhibition of natural antisense transcript to lhx2
MX2017015012A (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
SG11201903725UA (en) Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
BR112019001193A2 (pt) uso de sulfatos de colesterol oxigenados (ocs) para tratar doença de pele inflamatória e lesões de pele
WO2019166412A9 (en) Modulation of pla2-g1b in therapy
NZ607195A (en) Methods for treating and/or reversing neurodegenerative diseases and/or disorders
WO2016127059A3 (en) Light inhibitors for scleroderma and skin fibrotic disease treatment
AU2024201828A1 (en) Methods of treating and/or preventing actinic keratosis
MX2018013860A (es) Composiciones cosmeticas para reparacion cutanea.
MX2016016407A (es) Composiciones biofotonicas termoestables y usos de las mismas.
IL286268A (en) Pridopidine for the treatment of mitochondrial diseases and disorders and symptoms associated with these diseases
BR112019006174A2 (pt) proteina terapêutica
WO2016182812A8 (en) Activation of neuronal store-operated calcium entry pathway for the treatment of alzheimer's disease